Table 1.
Summary of changes in adjuvant therapy recommendations with Oncotype DX testing in the modelling analysis
Recurrence Score | Initial recommendation | Post Oncotype DX net change in CT use HT+CT (%) |
|
---|---|---|---|
| |||
HT (%) | HT+CT (%) | ||
Low | 30.9 (51/165) | 25.5 (42/165) | −21.0 |
Intermediate | 11.5 (19/165) | 23.6 (39/165) | 1.9 |
High | 1.8 (3/165) | 6.7 (11/165) | 4.8 |
Total | 44.2 (73/165) | 55.8 (92/165) |
CT: chemotherapy; HT: hormone therapy